AURA (a retrospective noninterventional study to assess the effectiveness of existing Anti-vascUlar endothelial growth factor treatment Regimens in patients with wet Age-related macular degeneration) monitored 2-year outcomes in patients with neovascular AMD who started treatment with ranibizumab between January 2009 and August 2009.11 This observational study showed that visual acuity gains were not maintained over 2 years, and the mean number of injections was low. The gene discussed is VEGFA; the disease is age-related macular degeneration.